5 Cancers Where China's Cancer Care Stands Out: A Plain-Language Guide for Patients and Families

After a cancer diagnosis, many families face the same question: Should we seek treatment abroad? For a long time, the default answer seemed to be the United States or Japan.

But the trend is beginning to reverse. A growing number of patients from Indonesia, Vietnam, the Middle East, and Africa are traveling to cancer hospitals in Shanghai, Guangzhou, and Beijing. They are not taking a chance on unknown care — they are coming because, in certain cancers, China offers therapies approved nowhere else in the world, some of the world's largest surgical volumes, and treatment results recognized by the international medical community.

Drawing on public data from China's National Cancer Center, the National Medical Products Administration (NMPA), the U.S. SEER database, and leading journals including The Lancet and the New England Journal of Medicine, this article is organized around the questions patients and families care about most. For five cancers — gastric, esophageal, nasopharyngeal, lung, and liver — it explains where China's distinctive strengths lie, and what those strengths mean for you or your family member.

A note on framing: this article does not claim China leads the world across all of cancer care. In these five specific cancers, Chinese hospitals hold advantages that are concrete and verifiable — a world-first approved therapy, unmatched surgical volumes, internationally adopted standards, or innovative drugs now passing review by Western regulators.

Before the Data: A Brief Guide to the Terms Used in This Article

• 5-year survival rate: the percentage of patients alive five years after diagnosis. It does not mean "only five years to live" — when a cancer does not recur within five years after treatment, the risk of later recurrence is generally much lower, which is why 5-year survival is the standard international measure of treatment effectiveness. Higher is better.

• CAR-T cell therapy: a personalized cell therapy in which a patient's own immune cells are collected, genetically engineered in the laboratory to recognize and attack cancer cells, and then infused back into the patient.

• Targeted therapy: drugs designed to act on a specific genetic mutation in tumor cells, affecting only cancer cells that carry that mutation. Compared with conventional chemotherapy, targeted therapy generally has less impact on healthy cells and milder side effects.

• PFS (progression-free survival) : the length of time after treatment begins during which the tumor does not grow or spread. Longer PFS means more time living without disease progression.

• ORR (objective response rate) : the percentage of patients whose tumors shrink significantly after treatment.

• HR (hazard ratio) : a measure comparing risk between two groups. HR 0.30 means the new-treatment group's risk of progression is 30% of the control group's — a 70% risk reduction.

• Proton / heavy-ion radiotherapy: precision radiation techniques that exploit the physical properties of proton or carbon-ion beams, which release most of their energy at the depth of the tumor, substantially reducing the radiation dose delivered to the healthy tissue in front of and behind it.

• Randomized controlled trial (RCT) : a clinical study in which patients are randomly assigned to receive either the new treatment or the standard treatment, and outcomes are compared. RCTs are the highest-grade study design in medical evidence.

1. The Overall Picture

A 2024 report from China's National Cancer Center, published in the Journal of the National Cancer Center (JNCC), analyzed 6.41 millionpatients diagnosed during 2019–2021 across 281 cancer registries. China's age-standardized 5-year relative survival rate for all cancers combined was 43.7% , compared with about 30.9% a decade earlier — an improvement of more than 12 percentage points in ten years, among the fastest gains recorded anywhere in the world.

Much of the gap between this figure and the U.S. rate (around 69%) reflects differences in the two countries' cancer profiles: China has a high burden of liver, gastric, and esophageal cancers, which carry poorer prognoses, while the U.S. caseload is weighted toward screen-detectable cancers such as prostate and breast cancer, which generally have better outcomes. Comparing overall survival rates directly is therefore misleading; the meaningful comparison is cancer by cancer, under equivalent conditions. On that basis, Chinese data have already caught up with or surpassed U.S. figures for several cancers:

Two points of context for this table. First, the lung cancer figures are like-for-like population statistics; the Chinese rate now slightly exceeds the U.S. rate. Second, the esophageal figures compare different patient groups — Chinese surgical patients versus U.S. patients of all stages — so they are not a strict apples-to-apples comparison; they do, however, indicate the strength of surgical outcomes in China's high-volume centers.

For the five cancers discussed below, China's advantage goes beyond survival statistics — each one addresses a concrete dilemma patients may face at home: "no drugs left to try," "surgery too risky," or "no options after recurrence."

2. Five Cancers: What Each One Solves for Patients

① Gastric Cancer: When Standard Treatments Run Out, China Holds a Therapy Available Nowhere Else.

The patient's situation: a substantial proportion of patients with advanced gastric cancer reach the point where surgery, chemotherapy, and targeted drugs have all failed. In most countries, no standard treatment remains at that stage, and 5-year survival for advanced gastric cancer is only about 10%. China accounts for roughly 47% of the world's gastric cancer patients — and it was against this enormous unmet need that China became the first country to approve a therapy researchers worldwide had pursued for years: CAR-T for a solid tumor.

What is different in China: on June 22, 2026, China's NMPA approved satri-cel (development code CT041) , a CAR-T cell therapy developed by Shanghai-based CARsgen Therapeutics, for CLDN18.2-positive, HER2-negative advanced gastric/gastroesophageal junction adenocarcinoma after failure of at least two prior treatment lines. The clinical program was led by Professor Shen Lin at Peking University Cancer Hospital across 24 national centers. CAR-T for blood cancers (leukemia, lymphoma) has existed for years, but solid tumors — cancers that grow in organs — had resisted every attempt. Satri-cel is the first, and currently the only, CAR-T product approved for a solid tumor anywhere in the world. No comparable product has been approved in the United States, Europe, or Japan.

What the data mean for patients: the Phase II results were published in The Lancet:

Progression risk fell by 70% (HR 0.30) and death risk by 40% (HR 0.60). In the earlier Phase I study (Nature Medicine, 2024), 54.9% of gastric cancer patients saw their tumors shrink significantly and 96.1% had their disease under control — compared with tumor-shrinkage rates usually below 10% for conventional later-line chemotherapy. For a patient who had been told "there are no drugs left," that means moving from a less-than-one-in-ten chance of response to better than one in two.

Who should take particular note: patients with advanced gastric/gastroesophageal junction cancer whose pathology reports show CLDN18.2-positive, HER2-negative status and whose standard options at home are exhausted — China is currently the only country in the world where this approved treatment is legally available. In addition, as of October 2025 China had 1,283 registered CAR-T clinical trials (versus 671 in the U.S.; Frontiers in Pharmacology, 2026 review), so patients seeking cell-therapy trials have the world's broadest range of options in China.

② Esophageal Cancer: Surgery Is the Main Route to a Cure — and About Half the World's Surgery Is Done in China

The patient's situation: esophageal squamous-cell carcinoma is common in Central Asia, Eastern Europe, Africa, and China. For locally advanced disease, surgery is the most important route to a cure, but esophageal surgery is deep, difficult, and carries significant complication risk. A well-documented surgical principle — the learning curve — holds that the more procedures a team performs, the more refined the technique, the fewer the complications, and the better the long-term results. That is the most practical value of China's high-volume centers for patients.

What is different in China: China accounts for over 40% of the world's new esophageal cancer cases, and roughly half of all esophageal cancer surgeries worldwide are performed there; 85–87% of Chinese cases are squamous-cell carcinoma, and Chinese surgeons have accumulated the world's most extensive experience in that subtype. At Shanghai Chest Hospital, a leading center, more than 800 esophageal surgeries are performed each year, and over 2,600 robot-assisted minimally invasive esophagectomies (RAMIE) have been completed — the largest single-center volume in the world. In April 2026, The Lancet Gastroenterology & Hepatology published an RCT led by Professor Li Zhigang's team at that hospital. It was the first randomized trial to report a long-term survival advantage for robotic surgery over conventional thoracoscopic (minimally invasive) surgery in solid-tumor patients:

What the numbers mean for patients: the 13.2-percentage-point gap corresponds to roughly 13 additional survivors per 100 patients at five years — and the robotic approach itself means smaller trauma and faster postoperative recovery. Nationwide, 73.4% of esophageal surgeries are now minimally invasive, and postoperative 5-year survival has risen from a historical 30–40% to over 60% among surgical patients. For reference, the U.S. all-stages 5-year survival rate for esophageal cancer is about 22% (ACS 2025); as noted above, the two figures measure different patient groups.

Who should take particular note: patients with locally advanced esophageal squamous-cell carcinoma who want robotic minimally invasive surgery. For patients from high-incidence regions whose home centers perform few such operations, the surgical safety and long-term outcomes at China's high-volume centers are difficult for centers that see far fewer of these cases to match.

③ Nasopharyngeal Cancer: International Standards Shaped by Chinese Research — and a Leading-Edge Second Chance After Recurrence

The patient's situation: nasopharyngeal cancer (NPC) is common in southern China and Southeast Asia (Guangdong records about 30 cases per 100,000 — more than 30 times the rate in most of the world — and nearly half of all global cases occur in China). The tumor lies deep at the skull base, radiotherapy is the main curative treatment, and precision is paramount. The news patients fear most is recurrence: after the first course of radiation, the surrounding healthy tissue has already been exposed, and conventional photon re-irradiation yields 5-year survival typically below 20% , with potentially fatal complications such as mucosal necrosis and massive bleeding. Many patients are told re-treatment is impossible.

What is different in China: the concentration of cases has allowed Chinese doctors to study this cancer more deeply than anywhere else. At the Sun Yat-sen University Cancer Center, Academician Ma Jun's team spent 35 years raising NPC's 5-year overall survival from around 60% to over 84% . Four of the team's studies were incorporated into the AJCC/UICC international staging standards, and its protocol for protecting 33 organs-at-risk during radiotherapy is recommended by eight major European and American professional bodies — meaning the criteria doctors worldwide use to stage NPC and design organ-sparing radiation plans include work produced by Chinese scholars. For recurrence, the Shanghai Proton and Heavy Ion Center (SPHIC) reported these carbon-ion re-irradiation results:

What the numbers mean for patients: newly diagnosed patients treated with particle therapy achieved 93.8% 5-year survival. For recurrent patients, 45.3% — compared with under 20% for conventional re-irradiation — more than doubles the chance of survival, putting many patients who were told "no more radiation is possible" back onto a treatment path with nearly a one-in-two chance of long-term survival, while carbon-ion's sparing of healthy tissue substantially reduces the risk of fatal complications. The 45.3% figure is among the best recurrent-NPC re-irradiation results reported worldwide.

Who should take particular note: first, newly diagnosed patients who want the highest international standard of radiotherapy from the start; second, recurrent patients who have been told at home that further radiation is impossible. The treatment axis of Guangzhou (Sun Yat-sen University Cancer Center) and Shanghai (SPHIC) represents one of the highest NPC treatment standards in the world — patients from high-incidence regions of Southeast Asia have particular reason to consider it.

④ Lung Cancer: Survival Has Caught Up With the U.S. — and Chinese-Original Drugs Are Gaining International Recognition

The patient's situation: among lung cancer patients, one specific mutation — EGFR exon 20 insertion (exon20ins) — long presented a frustrating picture: no oral targeted therapy was approved for first-line use against it, so after diagnosis patients were limited to chemotherapy, with limited effectiveness and repeated hospital visits for intravenous infusions.

What is different in China: on August 30, 2026, Chinese biotech Dizal Pharmaceutical announced that the U.S. FDA had formally accepted its application for sunvozertinib (brand name ZEGFROVY in the U.S.) as first-line treatment for EGFR exon20ins non-small cell lung cancer — the first oral targeted-therapy application worldwide to reach the first-line stage for this indication. The pivotal Phase III WU-KONG28 trial (324 patients, international multicenter RCT; published in the New England Journal of Medicine and presented as a Late-Breaking Abstract oral session at ASCO 2026):

What the numbers mean for patients: nearly twice as many patients saw their tumors shrink significantly (58.9% vs 31.1%), and progression-free time was extended by nearly three months (HR 0.65, a 35% reduction in progression risk, p = 0.0008). Just as importantly, this is an oral medication — patients take it at home without hospitalization for infusions, with a markedly better quality of life during treatment. The drug's later-line indication received FDA accelerated approval in July 2025; in China it was approved in 2023 and included in national insurance reimbursement; it is the only EGFR exon20ins targeted therapy included in both the NCCN and ASCO international guidelines; and in July 2026 Dizal entered an exclusive global licensing agreement with AstraZeneca. In other words, a drug developed in China has successively passed FDA review, entered major international guidelines, and been licensed globally by a leading international pharmaceutical company.

It is worth placing this in context. China's overall 5-year lung cancer survival has risen from 18.7% in the 2000s to 32.1% (updated at the 2025 Chinese Congress of Oncology), compared with 27% in the U.S. (ACS 2025) — despite Chinese patients being diagnosed at more advanced stages. This does not mean China leads every aspect of lung cancer care, but it does mean Chinese patients now have access both to competitive survival outcomes and to Chinese-original frontier medicines recognized by international regulators.

Who should take particular note: non-small cell lung cancer patients confirmed by genetic testing to carry the EGFR exon20ins mutation(for both first-line and later-line settings), as well as patients interested in Chinese-developed targeted therapies more broadly.

⑤ Liver Cancer: Over 40% of the World's Cases Means Unmatched Experience Across the Full Treatment Chain

The patient's situation: HBV-related liver cancer is widespread across Asia and Africa but relatively uncommon in the West. Liver cancer offers many treatment routes — surgical resection, liver transplantation, ablation, interventional embolization (TACE), immunotherapy plus targeted therapy — and choosing the right path for a given stage and physical condition depends heavily on a team's case experience. A center that sees few such patients in a year and a center that has treated very large numbers may give patients very different treatment recommendations.

What is different in China: China has long accounted for over 40% of the world's liver cancer cases and deaths, predominantly HBV-related. This large case volume has produced deep experience across the full treatment chain: a large Chinese single-center series reports 5-year overall survival of about 47.7%after curative hepatectomy in 1,132 patients, and Chinese studies on immune-checkpoint-inhibitor plus anti-angiogenic combinations have been incorporated into international guidelines.

What the numbers mean for patients: at China's top hepatobiliary centers, the question is not "can it be treated?" but "of all these options, which one fits my condition best?" — from curative resection to transplant evaluation, from local ablation to the latest immunotherapy-targeted combinations, every decision is backed by extensive real-world case experience. China's advantage here is best understood as depth and breadth of experience rather than a claim to the world's best survival figures; countries such as Japan also report strong liver cancer outcomes.

Who should take particular note: patients with HBV-related liver cancer, especially those with complex conditions who need to choose among multiple treatment paths. This case experience and range of options are difficult for centers that see comparatively few such patients each year to replicate.

3. Proton and Heavy-Ion Therapy: Who Should Know About It?

Proton and carbon-ion (heavy-ion) radiotherapy concentrates radiation energy at the depth of the tumor, killing cancer cells while substantially reducing exposure of surrounding healthy tissue. A decade ago China had a single such center (SPHIC, opened 2015); as of January 2026, 13 are in operation (8 proton, 1 combined proton-and-heavy-ion, 4 heavy-ion), with another 54 approved across 28 provinces.

The flagship SPHIC had treated a cumulative 9,317 patients by May 2026, including 1,267 in 2025 alone — over a thousand per year for five consecutive years, among the highest annual volumes of any particle center worldwide.

Who this treatment suits best: first, patients whose tumors lie close to vital organs such as the eyes, brainstem, or heart, where conventional radiation would easily damage healthy tissue; second, patients who need re-irradiation after recurrence (such as the NPC cases above); third, patients who want to minimize severe side effects and maintain quality of life during treatment. Its long-term outcomes:

Severe acute adverse events of Grade 3 or above totaled fewer than 5%, meaning the vast majority of patients maintain good physical condition throughout treatment. On cost: a full carbon-ion course at the Mazu Campus of Fujian Medical University Union Hospital is packaged at about RMB 198,000 (roughly USD 27,800) , and domestic proton therapy at Shanghai Ruijin Hospital runs about RMB 170,000 (roughly USD 23,800) . A typical course of proton therapy in the United States costs USD 150,000–250,000 — comparable technology at roughly one-quarter of the U.S. cost.

4. Cost: For Self-Paying Families, the Gap Is Measured in Multiples

For self-paying international patients, the China–U.S. cost difference in cancer care is not 10–20%; for most of the treatments below it is several-fold:

Prices are compiled from 2026 public quotes on three independent medical-tourism information platforms (MedChinaGuide, WanderPeng, ChinaCureLink). They are order-of-magnitude references rather than precise quotations; actual costs vary with hospital tier, length of stay, complications, and drug regimens.

What this means in practice for families: the savings are typically enough to cover round-trip flights for the patient and one companion, accommodation, translation, and all living expenses in China — with margin remaining. For many families, it means not having to choose between selling the family home and giving up treatment.

5. A Quick Check: Does This Apply to Your Family Member?

One practical caveat: the outcomes cited above come principally from China's leading hospitals. Its top medical resources are concentrated in national cancer centers and leading tertiary hospitals in cities such as Beijing, Shanghai, Guangzhou, and Hangzhou — choosing the right hospital and specialist is the precondition for achieving these results.Patients should prioritize hospitals affiliated with the National Cancer Center / national regional cancer centers and university cancer hospitals, and actively request a multidisciplinary team (MDT) consultation, in which surgeons, medical oncologists, radiation oncologists, and radiologists jointly review the case and build a comprehensive plan, avoiding the limitations of a single-department decision. A written packaged-cost quotation should be obtained before treatment begins.

In Closing

A decade ago, an international patient coming to China for cancer care generally meant a trade-off between cost and quality. Today, for patients with specific cancers, specific stages, and specific biomarkers, China can offer three forms of value at once: therapies not yet approved at home, treatment teams with unusually deep experience in those specific cancers, and substantially lower cost.

The question worth careful consideration is therefore no longer "Is cancer treatment in China good?" but rather: "For my specific condition, which Chinese hospital and which specialist are best suited to it, and what would the overall cost and process involve? "

Answering that systematically requires case evaluation, professional translation of medical records, hospital and specialist matching, medical-visa coordination, full in-country accompaniment, and follow-up after returning home. Professional cross-border medical coordination services can help patients manage this entire process, allowing patients and their families to focus on what matters most — the treatment itself.